Killing bladder cancer with new treatment

Your kidneys filter waste products from your blood, creating urine and sending it through thin tubes into your bladder. When your bladder is full, you urinate to eliminate the waste.

Urine can contain toxic chemicals that can damage the inner lining of the bladder and cause bladder cancer. Most bladder cancers are detected early and treatments with a drug known as BCG are successful; however, in 25 to 30% of these cases the treatments fail and patients become BCG-Unresponsive.

If this happens, the current treatment for BCG-Unresponsive is bladder removal, a complex and costly procedure, with numerous quality of life impacts.

Theralase is developing an alternative treatment for BCG-Unresponsive patients, where the bladder is filled with a light sensitive drug solution called TLD-1433 which localizes specifically to the bladder cancer.

Once TLD-1433 is inside the bladder cancer cells, fibre optics are inserted into the bladder and a laser is used to light activate the drug to destroy the bladder cancer cells from the inside out, leaving the bladder intact.  The liquid in the bladder is then voided and the dead cancer cells excreted.

Theralase is working to bring this product to market in the next 3 years.

About Theralase

Theralase® Technologies Inc. is a biopharmaceutical company headquartered in Toronto, Canada focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive clinical applications in patients.

Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states.

For more information on Theralase Technologies Inc. (TLT:TSX.V, TLTFF:OTCQB) please fill out the form below.